ClinicalTrials.gg
CompletedNCT03626415Updated May 18, 2020Results posted

A Hepatic Impairment Study for PF-04965842.

A Phase 1 interventional study of PF-04965842 in Hepatic Impairment, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-18.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.

Read the detailed description

A minimum of 24 subjects with normal, mild or moderate hepatic function will be enrolled into the study, with approximately 8 subjects in each cohort. The Child Pugh classification score will be utilized to assess entry criteria and to assign subjects into the appropriate hepatic impairment group. For individual subjects, the total maximum duration of study participation from the Screening visit to the end of clinical research unit (CRU) stay is approximately 31 days and approximately 63 days from the Screening visit to the Follow up contact.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 pounds).
  • Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Additional Inclusion Criteria for subjects with hepatic impairment:

  • Satisfy the criteria for Class A or Class B of the classification (mild: Child Pugh Scores 5 to 6 points, and moderate: Child Pugh Scores 7 to 9 points), within 14 days of product administration.
  • A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver , hepatic ultrasound, computerized tomography scan, or magnetic resonance imaging (MRI).

Exclusion criteria

Exclusion Criteria:

  • Subjects with infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days, history of disseminated herpes simplex infection or recurrent (>1 episode) or disseminated herpes zoster.
  • Subjects with a or with a history of malignancy, with the exception of adequately treated or excised non basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.

Additional exclusion criteria for subjects with hepatic impairment:

  • Hepatic carcinoma or hepatorenal syndrome or limited predicted (defined as less than 1 year).
  • Subjects who have previously had a transplanted kidney, liver, or heart.
  • At Screening, persistent severe, uncontrolled hypertension.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PF-04965842

    PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.

    Drug: PF-04965842

Interventions

  • PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) for PF-04965842

    Cmax is maximum plasma concentration. It was observed directly from data.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort

  2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842

    AUCinf is area under the concentration-time curve (AUC) from time 0 (pre-dose) extrapolated to infinite time.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent adverse events (TEAEs) were those with initial onset or increasing in severity between the first dose of investigational product and up to 36 days post-dose.

    Time frame: From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants.

  2. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.

    Time frame: Screening (within 28 days prior to Day 1), Day -1, 2, 24, 72 hours post-dose.

  3. Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842

    12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. Clinical significance of ECG recordings was determined at the investigator's discretion.

    Time frame: Screening (within 28 days prior to Day 1), Day -1, 2, 72 hours post-dose.

  4. Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842

    Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant following at least 5 minutes of supine rest. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Screening (within 28 days prior to Day 1), 0 (pre-dose), and 72 hours post-dose.

07

Results

Posted May 18, 2020

Participant flow

Participant flow — Overall Study
MilestonePF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Started888
Completed888
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) for PF-04965842

Cmax is maximum plasma concentration. It was observed directly from data.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for PF-04965842
nanogram per milliliter (ng/mL)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Maximum Observed Plasma Concentration (Cmax) for PF-049658421352 ± 441276 ± 411426 ± 63
Statistical analysis
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Mild Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric mean: 94.40 · 90% CI 62.96 to 141.55
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Moderate Hepatic Impairment Cohort) · ANOVA · Ratio of adusted geometric means: 105.53 · 90% CI 70.38 to 158.24
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842

AUCinf is area under the concentration-time curve (AUC) from time 0 (pre-dose) extrapolated to infinite time.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842
nanogram*hour per milliliter (ng*hr/mL)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-049658425587 ± 747449 ± 298603 ± 55
Statistical analysis
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Mild Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric means: 133.33 · 90% CI 86.17 to 206.28
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Moderate Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric mean: 153.99 · 90% CI 99.52 to 238.25
Post-hocUnbound Cmax (Cmax,u) for Active Moiety

Cmax,u is unbound Cmax. The active moiety is comprised of parent drug PF-04965842, active metabolites PF-06471658 and PF-07055087.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Reported as:
Geometric mean · nanomolar (nM)
Unbound Cmax (Cmax,u) for Active Moiety
nanomolar (nM)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Unbound Cmax (Cmax,u) for Active Moiety2390 ± 201815 ± 362011 ± 41
Statistical analysis
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Mild Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric means: 75.94 · 90% CI 57.39 to 100.47
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Moderate Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric means: 84.14 · 90% CI 63.59 to 111.33
Post-hocUnbound AUCinf (AUCinf,u) for Active Moiety

AUCinf,u is unbound AUCinf. The active moiety is comprised of parent drug PF-04965842, active metabolites PF-06471658 and PF-07055087.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Reported as:
Geometric mean · nanomolar*hour (nM*hr)
Unbound AUCinf (AUCinf,u) for Active Moiety
nanomolar*hour (nM*hr)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Unbound AUCinf (AUCinf,u) for Active Moiety12010 ± 4011500 ± 2413790 ± 30
Statistical analysis
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Mild Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric means: 95.74 · 90% CI 72.71 to 126.08
  • PF-04965842 (Normal Hepatic Function Cohort) vs PF-04965842 (Moderate Hepatic Impairment Cohort) · ANOVA · Ratio of adjusted geometric means: 114.82 · 90% CI 87.19 to 151.20
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent adverse events (TEAEs) were those with initial onset or increasing in severity between the first dose of investigational product and up to 36 days post-dose.

Time frame:
From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants.
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842
ParticipantsPF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
AEs (all causalities)230
AEs (treatment related)130
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.

Time frame:
Screening (within 28 days prior to Day 1), Day -1, 2, 24, 72 hours post-dose.
Reported as:
Number · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)478
SecondaryNumber of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842

12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. Clinical significance of ECG recordings was determined at the investigator's discretion.

Time frame:
Screening (within 28 days prior to Day 1), Day -1, 2, 72 hours post-dose.
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842
ParticipantsPF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842000
SecondaryNumber of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842

Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant following at least 5 minutes of supine rest. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame:
Screening (within 28 days prior to Day 1), 0 (pre-dose), and 72 hours post-dose.
Reported as:
Number · Participants
Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842
ParticipantsPF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842000

Adverse events

Collected over From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-04965842 (Normal Hepatic Function Cohort)0/8 (0%)0/8 (0%)2/8 (25%)
PF-04965842 (Mild Hepatic Impairment Cohort)0/8 (0%)0/8 (0%)3/8 (37.5%)
PF-04965842 (Moderate Hepatic Impairment Cohort)0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventPF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)
DiarrhoeaGastrointestinal disorders0/82/80/8
HeadacheNervous system disorders0/82/80/8
NauseaGastrointestinal disorders1/80/80/8
Upper respiratory tract infectionInfections and infestations1/80/80/8

Baseline characteristics

The baseline analysis population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(Years)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)Total
Mean58.5 ± 5.8657.9 ± 4.1958.6 ± 8.2158.3 ± 6.03
Sex: Female, Male
Sex: Female, Male(Participants)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)Total
Female3339
Male55515
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)Total
Hispanic or Latino1001
Not Hispanic or Latino78823
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-04965842 (Normal Hepatic Function Cohort)PF-04965842 (Mild Hepatic Impairment Cohort)PF-04965842 (Moderate Hepatic Impairment Cohort)Total
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1405
White74718
More than one race0000
Unknown or Not Reported0000
08

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Prism Clinical Research, LLC
    Saint Paul, Minnesota 55114, United States
09

References and documents

Publications

  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21. Erratum In: Clin Pharmacokinet. 2022 Apr;61(4):591. doi: 10.1007/s40262-022-01112-7. PubMed 35061234 ↗
  • Wang EQ, Le V, O'Gorman M, Tripathy S, Dowty ME, Wang L, Malhotra BK. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J Clin Pharmacol. 2021 Oct;61(10):1311-1323. doi: 10.1002/jcph.1858. Epub 2021 Apr 17. PubMed 33749838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Apr 2019, 6 months.

Results were first posted in May 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Aug 13, 2018
StartActual
Oct 1, 2018
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Results first posted
May 18, 2020
Last update
May 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03626415
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 13, 2018
Start date
Oct 1, 2018
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Results posted
May 18, 2020
Last update
May 18, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion